A Randomized, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia (REMAPCAP), a randomized trial of ARBs or ACE inhibitors versus usual care in patients hospitalized for acute COVID-19, was stopped early after a planned interim analysis because of significantly increased mortality and acute kidney injury rates in the ARB arm compared to usual care among the critically ill patient stratum. The gene discussed is ACE; the disease is acute kidney injury.